Amyloidosis - Open Access .click

Results 201 to 210 of about 125,062 (284)

Lipid Nanoparticles in Drug Delivery: Overcoming Challenges and Unlocking New Frontiers

Small Structures, Volume 7, Issue 3, March 2026.
Lipid nanoparticles (LNPs) have revolutionized nucleic acid delivery, yet challenges in formulation, stability, and targeted efficacy persist. This review explores how advances in microfluidic manufacturing, precision targeting, and endosomal escape are reshaping LNP design.
Jordan Kambanis +7 more
wiley +1 more source

Primary Meningeal Extraskeletal Osteosarcoma in a Domestic Shorthaired Cat: Case Report and Review of Comparative Pathology

Veterinary Medicine and Science, Volume 12, Issue 2, March 2026.
A domestic shorthaired cat with neurological signs compatible with a forebrain lesion was investigated with magnetic resonance imaging, revealing a mass with intracranial and extracranial components. Due to the poor prognosis the cat was euthanized, and gross and histopathological examination identified an extraskeletal osteosarcoma with its origin in ...
Jacqueline Poldy +5 more
wiley +1 more source

Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients

JACC: Basic to Translational Science
Marianna Fontana, MD, PhD +2 more
doaj +1 more source

Bridging the Gap in AL and ATTR Cardiac Amyloidosis: Integrating Histopathology, Biomarkers, and Multimodal Imaging for Subtype-Specific Diagnosis. [PDF]

Rev Cardiovasc Med
Ali K +7 more
europepmc +1 more source

Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis [PDF]

, 2019
Lenihan, Daniel J +2 more
core +1 more source

Angiopoietin‐1, Angiopoietin‐2 and Vascular Endothelial Growth Factor Levels in Canine Leishmaniosis

Veterinary Medicine and Science, Volume 12, Issue 2, March 2026.
Ang‐1, Ang‐2 and VEGF levels significantly varied in different stages of canine leishmaniosis. ABSTRACT Background Canine leishmaniosis (CanL) is a zoonotic vector–borne disease and is primarily associated with systemic inflammation, endothelial dysfunction and immune dysregulation.
Gamze Gultekin +10 more
wiley +1 more source

Drug Product Development of Lipid Nanoparticle‐Based mRNA Therapeutics and Vaccines

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Overview of the development path from an mRNA–lipid nanoparticle (LNP) concept to a licensed drug product, covering LNP design, manufacturing process development, formulation, and analytical characterization. ABSTRACT Lipid nanoparticles (LNP) are currently the most relevant non‐viral delivery systems for mRNA and occasionally for smaller nucleic acids
Gideon Kersten +4 more
wiley +1 more source

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG‐MM5 Trial

European Journal of Haematology, Volume 116, Issue 3, Page 226-234, March 2026.
ABSTRACT Response assessment during treatment of multiple myeloma (MM) typically relies on immunofixation and serum electrophoresis. However, low levels of IgG and especially IgA paraprotein are difficult to quantify reliably. The Hevylite Assay quantifies the kappa and lambda fractions of IgG and IgA separately and is useful to determine response to ...
Tim Richardson +125 more
wiley +1 more source

Enhanced Detection of Multiple Myeloma Cells by Next‐Generation Flow Cytometry Following Density Gradient Medium Separation

European Journal of Haematology, Volume 116, Issue 3, Page 256-266, March 2026.
ABSTRACT Introduction Following treatment, relapse of Multiple Myeloma (MM) occurs due to measurable residual disease (MRD). As therapeutic options expand, advances in response assessment become more critical, necessitating more sensitive MRD detection methods.
Aisling O'Brien, Vitaliy Mykytiv, Fiona O'Halloran +2 more
wiley +1 more source

humans
3. good health
amyloid

diseases of the blood and blood-forming organs
prognosis
male

middle aged
serum amyloid a protein
aged